{"pub": "telegraph", "url": "https://telegraph.co.uk/business/2019/10/24/astrazeneca-ups-sales-guidance-amid-boost-china-cancer-drugs", "downloaded_at": "2019-10-24 15:05:55.812444+00:00", "title": "AstraZeneca ups sales guidance amid boost from China and cancer drugs", "language": "en", "text": "Pharmaceuticals conglomerate AstraZeneca is set to rake in higher full-year sales than expected amid a boost from Chinese demand and new cancer drugs.\n\nProduct sales jumped 16pc to $6.1bn (\u00a34.7bn) in the three months to October, its fifth successive period of revenue growth.\n\nThe FTSE 100 firm subsequently upped its sales guidance for the second time this year with revenues now expected to rise by a low to mid-teens percentage compared with a low double-digit percentage rise previously.\n\nAstraZeneca\u2019s performance was helped by the launch of a string of new drugs and a 25pc sales rise in emerging markets led by China, where sales grew 35pc to $1.3bn.\n\nAnalysts said AstraZeneca \u201ccontinues to impress\u201d. ...", "description": "Pharmaceuticals conglomerate AstraZeneca is set to rake in higher full-year sales than expected amid a boost from Chinese demand and new cancer drugs.", "authors": ["Hannah Uttley", "Ambrose Evans-Pritchard", "Jon Yeomans"], "top_image": "https://www.telegraph.co.uk/content/dam/business/2019/04/07/TELEMMGLPICT000177894431-xlarge_trans_NvBQzQNjv4Bql_tzPcsKQBkyUuy8aItKEbvSnkLCnn7FAXjPavPj9IU.jpeg?imwidth=1200", "published_at": "2019-10-24"}